Company Summary - Medicure Technology (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Medicure Technology achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's 2025 AI medical device innovation project list with a multimodal AI database project for gastrointestinal tumor diagnosis and treatment in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting a stronger certainty for AI medical commercialization in 2026 [1][1][1] - Key areas for investment focus include AI drug development, grassroots AI medical applications, medical data circulation and trading, AI pathology diagnosis, AI medical models, and C-end expansion channels [1][1][1]
连续十三日回购超6100万港元 医渡科技(02158)携手同济医院入选国家级“揭榜挂帅”名单